AUTHORS
Sandhya Maddali, N/A, Sherif Seif, MD2, Xiaowen Sun3, Lei Feng, MS4, Dingani Nkosi, MD5, Keyur P. Patel, MD6, Danielle Hammond, MD7, Kelly Sharon Chien, MD8, Lorenzo Gensini, MD9, Mahmoud R. Gaballa, MD10, Krina Patel Jr, MD, MSc11, Oren Pasvolsky, MD12, Jing Christine Ye, M.D., MSc13, Sarvari Yellapragada, MD14, Donna Marie Weber, MD15, Robert Orlowski, MD, PhD16, Sheeba Koshy Thomas, M.D.17
AFFILIATIONS
1 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
2 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
3 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
4 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
5 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
6 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
7 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
8 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
9 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
10 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
11 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
12 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
13 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
14 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
15 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
16 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
17 University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Introduction: Clonal hematopoiesis (CH) is a premalignant condition characterized by the presence of specific somatic mutations, and associated with an increased risk of leukemia, cardiovascular disease, and other inflammatory conditions. Around 75% of patients with CH have either DNMT3A, TET2, or ASXL1 mutations. The prevalence of CH increases with age, occurring in at least 10% of adults over 70. Next-generation sequencing (NGS) in patients with Waldenström macroglobulinemia (WM) can reveal mutations associated with CH. This study aimed to determine whether the presence of these CH-related mutations impacts presenting signs, symptoms, and overall survival (OS) in patients with WM.
Methods: We reviewed data from all patients (n=234) at our institution who were diagnosed with WM between 06/01/2001 and 12/20/2025, and who had a 162 NGS gene mutation panel performed on an unselected bone marrow aspirate. CH positive status was defined by the presence of DNMT3A, TET2, or ASXL1 mutations. OS was calculated from date of first NGS panel to date of last follow-up or death.
Results: Median age at first NGS panel was 69 years (32-91); 146 (62.3%) were male and 219 (93.5%) identified as White/Caucasian. At time of NGS testing, 172 patients had symptomatic WM and 62 had smoldering disease. CH mutations were detected in 30 (17.4%) and 14 (22.6%) patients with symptomatic and smoldering WM respectively. TET2, DNMT3A, and ASXL1 mutations were seen in 15 (8.7%), 11 (6.4%) and 6 (3.5%) patients with symptomatic WM, and 5 (8.1%), 9 (14.5%), and 1 (1.6%) patient(s) with smoldering WM.
Among those with symptomatic WM and CH, there was a higher incidence of cardiovascular disease (p=0.04) and chronic kidney disease (p=0.02), and a trend toward an increased incidence of osteoporosis (p=0.08). However, presenting features of WM did not differ between cohorts. The total median number of somatic mutations (excluding MYD88 and CXCR4) on NGS panels was higher among patients with CH (3 vs 1, p= <.0001). CH positivity was also associated with a shorter 2-year OS (72% vs 89%, p=0.026). This finding was driven by TET2 positivity (2-year OS: 58% vs 89%, p=0.0005), as neither ASXL1 nor DNMT3A independently impacted OS. Yet TET2 mutation variant allele frequency (dichotomized at values ≤10 vs >10) was not of significance. Concurrent CH mutations with either CXCR4 (p=0.018) or TP53 (p=0.015) mutations had further negative prognostic impact. Of the 24 patients who died, reasons for death were WM/diffuse large B cell lymphoma (58.4%), non-hematologic malignancy (12.5%), infection (8.4%), small bowel obstruction (4.2%), and unknown causes (16.5%).
Within the smoldering cohort, CH positivity neither influenced time to development of symptomatic WM nor OS.
Conclusion: As observed in other malignancies (e.g. multiple myeloma, breast cancer), our findings suggest that CH, and more specifically TET2 mutations, negatively impact OS in patients with symptomatic WM. Whether this negative prognostic impact is driven by WM, second malignancies, comorbid conditions, or a combination thereof, requires further investigation. Since chemotherapeutics commonly used in WM (e.g. alkylating agents) heighten the risk of developing leukemia, our results raise the question of whether CH/TET2 status should be considered when selecting systemic therapy. These results warrant validation in a larger cohort of symptomatic WM patients.
DISCLOSURES
Sandhya Maddali, N/A: No relevant conflicts of interest to declare.